Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?

CONCLUSION: Annual mean incremental societal cost per patient was highest for PsA, mainly because of productivity losses and biological treatment. A minor fraction of the costs were identified as attributable to PsO/PsA specifically, indicating an increased morbidity in these patients that needs to be further investigated.
PMID: 26773111 [PubMed - as supplied by publisher]

Source: J Rheumatol - January 15, 2016 Category: Rheumatology Authors: Löfvendahl S, Petersson IF, Theander E, Svensson Å, Zhou C, Steen Carlsson K Tags: J Rheumatol Source Type: research